Cognitive impairment and major depressive disorder in HIV infection and cerebrospinal fluid biomarkers

Cognitive impairment and major depressive disorder in HIV infection and cerebrospinal fluid biomarkers

Cognitive impairment and major depressive disorder (MDD) are common HIV-1 central nervous system (CNS) complications. Their frequencies in AIDS patients are 36% and 45%, respectively. The diagnoses of HIV cognitive impairment are made by clinical criteria, no single laboratory test or biomarker establishes the diagnosis. Factors of indirect neuronal injury related with the pathophysiology of the HIV infection in the CNS, are the factors studied as biomarkers. In the present no biomarker is established to the diagnosis of HIV cognitive impairment, much still needs to be done. We review in this paper some biomarkers in cerebrospinal fluid that could be valuable to the diagnosis of HIV cognitive impairment. Diagnosing depression in the context of HIV can be challenging, to identify a biomarker that could help in the diagnosis would be very important, although MDD risks and neurobiology are still poorly understood.

Saved in:
Bibliographic Details
Main Author: Almeida,Sergio Monteiro de
Format: Digital revista
Language:English
Published: Academia Brasileira de Neurologia - ABNEURO 2013
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2013001000689
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0004-282X2013001000689
record_format ojs
spelling oai:scielo:S0004-282X20130010006892013-10-10Cognitive impairment and major depressive disorder in HIV infection and cerebrospinal fluid biomarkersAlmeida,Sergio Monteiro de HIV dementia major depressive disorder central nervous system HIV cerebrospinal fluid biomarkers HIV demencia desordem depressiva maior sistema nervoso central HIV liquido cefalorraquidiano biomarcadores Cognitive impairment and major depressive disorder (MDD) are common HIV-1 central nervous system (CNS) complications. Their frequencies in AIDS patients are 36% and 45%, respectively. The diagnoses of HIV cognitive impairment are made by clinical criteria, no single laboratory test or biomarker establishes the diagnosis. Factors of indirect neuronal injury related with the pathophysiology of the HIV infection in the CNS, are the factors studied as biomarkers. In the present no biomarker is established to the diagnosis of HIV cognitive impairment, much still needs to be done. We review in this paper some biomarkers in cerebrospinal fluid that could be valuable to the diagnosis of HIV cognitive impairment. Diagnosing depression in the context of HIV can be challenging, to identify a biomarker that could help in the diagnosis would be very important, although MDD risks and neurobiology are still poorly understood.info:eu-repo/semantics/openAccessAcademia Brasileira de Neurologia - ABNEUROArquivos de Neuro-Psiquiatria v.71 n.9B 20132013-09-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2013001000689en10.1590/0004-282X20130152
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Almeida,Sergio Monteiro de
spellingShingle Almeida,Sergio Monteiro de
Cognitive impairment and major depressive disorder in HIV infection and cerebrospinal fluid biomarkers
author_facet Almeida,Sergio Monteiro de
author_sort Almeida,Sergio Monteiro de
title Cognitive impairment and major depressive disorder in HIV infection and cerebrospinal fluid biomarkers
title_short Cognitive impairment and major depressive disorder in HIV infection and cerebrospinal fluid biomarkers
title_full Cognitive impairment and major depressive disorder in HIV infection and cerebrospinal fluid biomarkers
title_fullStr Cognitive impairment and major depressive disorder in HIV infection and cerebrospinal fluid biomarkers
title_full_unstemmed Cognitive impairment and major depressive disorder in HIV infection and cerebrospinal fluid biomarkers
title_sort cognitive impairment and major depressive disorder in hiv infection and cerebrospinal fluid biomarkers
description Cognitive impairment and major depressive disorder (MDD) are common HIV-1 central nervous system (CNS) complications. Their frequencies in AIDS patients are 36% and 45%, respectively. The diagnoses of HIV cognitive impairment are made by clinical criteria, no single laboratory test or biomarker establishes the diagnosis. Factors of indirect neuronal injury related with the pathophysiology of the HIV infection in the CNS, are the factors studied as biomarkers. In the present no biomarker is established to the diagnosis of HIV cognitive impairment, much still needs to be done. We review in this paper some biomarkers in cerebrospinal fluid that could be valuable to the diagnosis of HIV cognitive impairment. Diagnosing depression in the context of HIV can be challenging, to identify a biomarker that could help in the diagnosis would be very important, although MDD risks and neurobiology are still poorly understood.
publisher Academia Brasileira de Neurologia - ABNEURO
publishDate 2013
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2013001000689
work_keys_str_mv AT almeidasergiomonteirode cognitiveimpairmentandmajordepressivedisorderinhivinfectionandcerebrospinalfluidbiomarkers
_version_ 1756374600400240640

Similar Items